HCM
ASBP

Highbridge Capital Management’s Aspire Biopharma ASBP Stock Holding History

Highbridge Capital Management’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,163
Closed -$14.4M – 488
2022
Q4 		$14.4M Sell
1,163
-554
-32% -$6.79M 0.4% 96
2022
Q3 		$20.9M Buy
1,717
+723
+73% +$8.73M 0.29% 49
2022
Q2 		$11.9M Buy
+994
New +$11.9M 0.27% 122

Other funds holding ASBP

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Highbridge Capital Management's ASBP Position: Q1 2023 in Review

Highbridge Capital Management sold out of Aspire Biopharma (ASBP) in Q1 2023, closing a stake of 1,163 shares — an estimated $14.4M sold.

Highbridge Capital Management first reported a position in ASBP in Q2 2022 and held it in 3 quarters. The position peaked at $20.9M in Q3 2022. 57 funds tracked by Wall St. Rank hold ASBP as of Q1 2023.

  • Highbridge Capital Management reported no remaining Aspire Biopharma position as of Q1 2023 after selling out during the quarter.
  • Highbridge Capital Management sold 1,163 Aspire Biopharma shares in Q1 2023, an estimated $14.4M.
  • Highbridge Capital Management first reported a position in Aspire Biopharma in Q2 2022 and held it in 3 quarters.
  • Highbridge Capital Management's Aspire Biopharma position peaked at $20.9M in Q3 2022.
  • 57 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2023.

Based on Highbridge Capital Management's 13F filing for Q1 2023, filed 11 May 2023.